The rate of malignancy as reported in studies with proposed antigens implicated in MN.
| Antigen . | Rate of positivity in primary membranous nephropathy . | Approximate incidence of MN antigens [13] . | Rate of underlying malignancy when reported positive . |
|---|---|---|---|
| PLA2R [13, 34] | 70%–80% | 55% | Up to 5%a |
| THSD7A [8, 34] | 3% | 2% | 6%–25% |
| NELL-1 [9, 10] | 1%–2% | 10% | 10%–30% |
| PCDH7 [12] | 2% | 2% | 20% |
| Antigen . | Rate of positivity in primary membranous nephropathy . | Approximate incidence of MN antigens [13] . | Rate of underlying malignancy when reported positive . |
|---|---|---|---|
| PLA2R [13, 34] | 70%–80% | 55% | Up to 5%a |
| THSD7A [8, 34] | 3% | 2% | 6%–25% |
| NELL-1 [9, 10] | 1%–2% | 10% | 10%–30% |
| PCDH7 [12] | 2% | 2% | 20% |
Mainly reported in investigations from China (even higher frequencies); rarely reported/seen in Caucasian populations.
Abbreviation: PCDH7, Protocadherin 7; PLA2R, phospholipase A2 receptor; THSD7A, thrombospondin type-1 domain-containing 7A; NELL-1, neural epidermal growth factor-like 1.
The rate of malignancy as reported in studies with proposed antigens implicated in MN.
| Antigen . | Rate of positivity in primary membranous nephropathy . | Approximate incidence of MN antigens [13] . | Rate of underlying malignancy when reported positive . |
|---|---|---|---|
| PLA2R [13, 34] | 70%–80% | 55% | Up to 5%a |
| THSD7A [8, 34] | 3% | 2% | 6%–25% |
| NELL-1 [9, 10] | 1%–2% | 10% | 10%–30% |
| PCDH7 [12] | 2% | 2% | 20% |
| Antigen . | Rate of positivity in primary membranous nephropathy . | Approximate incidence of MN antigens [13] . | Rate of underlying malignancy when reported positive . |
|---|---|---|---|
| PLA2R [13, 34] | 70%–80% | 55% | Up to 5%a |
| THSD7A [8, 34] | 3% | 2% | 6%–25% |
| NELL-1 [9, 10] | 1%–2% | 10% | 10%–30% |
| PCDH7 [12] | 2% | 2% | 20% |
Mainly reported in investigations from China (even higher frequencies); rarely reported/seen in Caucasian populations.
Abbreviation: PCDH7, Protocadherin 7; PLA2R, phospholipase A2 receptor; THSD7A, thrombospondin type-1 domain-containing 7A; NELL-1, neural epidermal growth factor-like 1.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
